Please login to the form below

Not currently logged in
Email:
Password:

patents

This page shows the latest patents news and features for those working in and with pharma, biotech and healthcare.

With Spiriva under pressure, Boehringer moves to bolster pipeline

With Spiriva under pressure, Boehringer moves to bolster pipeline

Spiriva is now off-patent in most markets but has been buffered from the steep declines that generally follow from generic competition because of the complexities of showing equivalence to the

Latest news

More from news
Approximately 68 fully matching, plus 1,481 partially matching documents found.

Latest Intelligence

  • Combining therapies and combining research Combining therapies and combining research

    Wholly focused on the discovery and development of new antibiotic combinations, it has already registered 128 patents for novel combinations active against highly resistant bacteria.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018. ... The world’s biggest selling drug, Humira,

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    A new cliff is looming: Between 2018 and 2025, branded drugs worth more than $250bn in sales will see their patents expire.

  • Is China ready for a pharmaceutical gold rush?

    A lack of clear patent rules and regulatory transparency, as well as large-scale drug counterfeiting, gave rise to the perception that China’s market was difficult to navigate.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    This saw phase 3 flops of drugs for stroke, prostate cancer and depression – failures that dented confidence in the firm as patent expiries for its blockbusters Crestor and Nexium loomed on ... revenue growth after years of patent-expiry-induced decline

More from intelligence
Approximately 2 fully matching, plus 112 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics